唐人神(002567.SZ):前三季度淨利潤預降155.21%-158.04%
格隆匯10月15日丨唐人神(002567.SZ)公佈前三季度業績預吿,公司預計2021年前三季度實現歸屬於上市公司股東的淨利潤為3.9億元-4.1億元,同比下降155.21%-158.04%;預計第三季度實現歸屬於上市公司股東的淨虧損為5.66億元-5.86億元,同比下降306.00%-313.28%。
業績變動主要原因為:
報吿期內,生豬價格持續下跌,飼料原料等成本較高,生豬養殖成本上升,養殖業務盈利水平同比下降;由於生豬價格持續下跌,公司根據企業會計準則和謹慎性原則,計提了存貨跌價準備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.